polatuzumab vedotin-piiq
Polivy Approved for Previously Untreated DLBCL, Not Otherwise Specified, or High-Grade B-Cell Lymphoma
The FDA approved polatuzumab vedotin-piiq (Polivy, Genentech) with R-CHP (rituximab, cyclophosphamide, doxorubicin, ...
APRIL 21, 2023
FDA Approves Polivy for Diffuse Large B-Cell Lymphoma
The FDA granted accelerated approval to polatuzumab vedotin-piiq, in combination with bendamustine and a rituximab ...
JUNE 12, 2019
Load more